Technology | June 27, 2014

Mobius Medical Systems Receives FDA Clearance for Mobius3D Software

Mobius 3D Mobius Medical Systems LP FDA Clearance

June 27, 2014 — Mobius Medical Systems LP’s Mobius3D software has received U.S. market clearance as a Class II medical device from the U.S. Food and Drug Administration (FDA).

Mobius3D software is used for quality assurance (QA) and treatment plan verification in radiation therapy. It calculates 3-D radiation dose directly on a patient's computed tomography (CT) scan or a phantom. The calculation is based on treatment plans initially calculated by a planning system. The MobiusFX module allows users to perform calculations based on linac delivery log data.

Mobius3D is the first software to verify patient plans in 3-D using an independently developed TPS quality algorithm. Mobius3D works with all major linear accelerators, offering a streamlined workflow. Mobius3D makes patient plan QA faster and easier while supplying details not available from basic meaningful use verification software.

The FDA clearance includes MobiusFX, an optional add-on that utilizes the same independently developed collapsed-cone algorithm with delivery log files to determine 3-D dose delivered to the patient. MobiusFX provides clinicians a new and better way to perform patient-specific QA. Current methods that rely on ion chamber or diode arrays, EPIDs, or film are excessively time consuming, taking anywhere from 30 to 90 minutes per patient to complete and analyze. The long time required often necessitates the need for clinicians to work after hours or weekends in order to accomplish this important QA task. MobiusFX only requires enough time to deliver the beams. This allows QA to be easily achieved during breaks between patients or over a lunch hour, offering an opportunity to reclaim those nights and weekends.

As a true 3-D solution for patient plan and delivery QA, Mobius3D and MobiusFX can provide information that is not available from traditional methods. Customizable DVH objectives, that include RTOG protocols and Task Group 101 recommendations by default, can be used by Mobius3D to tell clinicians if their treatments are meeting goals. MobiusFX compares data from the machine delivery to expected positions from the TPS plan. This provides users confidence that all parameters were delivered exactly as prescribed. Moreover, MobiusFX will extend the IMRT QA process from a pre-treatment check into per-fraction verifications. Lastly, Mobius3D’s intuitive browser-based interface can be accessed with any computer, tablet, or smartphone, making it extremely easy to evaluate results.

For more information: www.mobiusmed.com

Related Content

New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
News | Treatment Planning | May 24, 2018
Daniela Schmitt, Ph.D., took top honors in the overall category of the 2018 TROG Plan Study: Stereotactic Radiosurgery...
Overlay Init